Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy

Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Moussavou, Ghislain, Ko, Kisung, Lee, Jeong-Hwan, Choo, Young-Kug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624878/
https://www.ncbi.nlm.nih.gov/pubmed/26550566
http://dx.doi.org/10.1155/2015/306164
_version_ 1782397881263587328
author Moussavou, Ghislain
Ko, Kisung
Lee, Jeong-Hwan
Choo, Young-Kug
author_facet Moussavou, Ghislain
Ko, Kisung
Lee, Jeong-Hwan
Choo, Young-Kug
author_sort Moussavou, Ghislain
collection PubMed
description Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants.
format Online
Article
Text
id pubmed-4624878
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46248782015-11-08 Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy Moussavou, Ghislain Ko, Kisung Lee, Jeong-Hwan Choo, Young-Kug Biomed Res Int Review Article Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants. Hindawi Publishing Corporation 2015 2015-10-15 /pmc/articles/PMC4624878/ /pubmed/26550566 http://dx.doi.org/10.1155/2015/306164 Text en Copyright © 2015 Ghislain Moussavou et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Moussavou, Ghislain
Ko, Kisung
Lee, Jeong-Hwan
Choo, Young-Kug
Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title_full Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title_fullStr Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title_full_unstemmed Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title_short Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy
title_sort production of monoclonal antibodies in plants for cancer immunotherapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624878/
https://www.ncbi.nlm.nih.gov/pubmed/26550566
http://dx.doi.org/10.1155/2015/306164
work_keys_str_mv AT moussavoughislain productionofmonoclonalantibodiesinplantsforcancerimmunotherapy
AT kokisung productionofmonoclonalantibodiesinplantsforcancerimmunotherapy
AT leejeonghwan productionofmonoclonalantibodiesinplantsforcancerimmunotherapy
AT chooyoungkug productionofmonoclonalantibodiesinplantsforcancerimmunotherapy

Ejemplares similares